Abstract 5488
Background
In the course of tumor growth, the cells that are far from the blood vessel are exposed to hypoxic conditions. As part of this process transcription factors (TFs) of the Snail family (Snail, Slug, Twist1, and Zeb1) are activated launching the epithelial-mesenchymal transition (EMT) program. Snail family factors are the most studied as stimulators of EMT, promoting tumor progression, migration and invasion of tumor cells. The aim of our research is to study adaptive mechanisms of human breast cancer (BC) cells to hypoxia and the analysis of the role of the TF Snail in this process.
Methods
We used human BC cells MCF-7, MDA-MB-231 and HBL-100 which were cultured in standard DMEM containing 10% fetal calf serum at 37oC and 5% СО2. For hypoxia modeling, the cells were cultured in a CO2-incubator maintaining O2 concentration at 1%.
Results
Knockdown of the Snail by small interfering RNA (siRNA) leads to increased sensitivity of breast cancer cells to hypoxia, due to increased blocking of cells in the S-phase of cell cycle. Cells were more resistant to hypoxia at a lower density, where Snail expression was increased, but further hyperexpression of Snail had not lead to increased resistance to hypoxia. Knockdown of Snail leads to an compensatory increase of Slug`s expression, while the knockdown of Twist1 and Zeb1 leads to decreased Slug expression. Knockdown of Twist1 decreases cell proliferation both in hypoxia and normoxia, through activation of cell cycle inhibitor p21WAF1, specifically in the G2/M phase, in p53-wild type HBL-100 cells. We used a chemical inhibitor of p53-Snail interaction GN25, to examine if blocking of this interaction could lead to increased sensitivity in hypoxia. We have shown that this compound has a greater cytotoxic effect in normoxia than hypoxia, due to increased Snail activity.
Conclusions
Modulation of Snail-associated signaling pathways is a perspective target for increase of cancer cell tolerance to chronic hypoxia, and inhibition of metastatic process in breast cancer cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grant no. 14.W03.31.0020 between the Ministry of Science and Education of the Russian Federation and Institute of Gene Biology, Russian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract